- NHS to give volunteers ‘synthetic blood’ made in a laboratory within two years (independent.co.uk)
….clinical trial of artificial red blood cells will occur before 2017, National Health Service (UK) scientists said. The blood is made from stem cells extracted from either the umbilical cord blood of newborn babies or the blood of adult donors.
- Carson City HHS would lead in disease preparedness (nevadaappeal.com)
..Health and Human Services agency plays a supporting role in the emergency services network, ….HHS isn’t a primary care giver, it does provide Carson City residents a safety net to help meet some of their health and social services needs.....programs are providing the needy with medication, workforce development and training along with periodic job fairs, nutritional services for women, infants and children,…
- 4 ways the FAST Generics Act will help healthcare (formularyjournal.modernmedicine.com)
1) greater competition, 2) reduce cost - restricted access programs costs the healthcare system $5.4 billion annually, including $1.8 billion to the federal government, 3) reduce cost of biosimilars,..could result in approximately $140 million in lost savings, 4) closes the existing loophole around current REMS prohibitions.
- Medicare Prescription Drug Benefit Not a Cost Saver (specialtypharmacytimes.com)
Medicare Part D cost saving projections is based on flawed methodology….impact of the may be overstated,..since 2006, Part D provided significantly greater access to prescription drugs for approximately 50 million Medicare subscribers, but this has not caused a clear drop in emergency room visits, hospital stays, inpatient costs, or mortality.
- Study shows hepatitis C treatment can be shortened (americanpharmacynews.com)
… study findings that showed more than 25 percent of hepatitis C patients may be treated with an eight-week therapy — four weeks shorter than drug manufacturers first believed. The findings reveal potential for great cost savings in a health care system where hepatitis C treatments have presented problems for payer organizations.
- Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products (fda.gov)
Injectable vial misuse,… led to vial..contamination and an increased risk of bloodborne illness transmission...Inappropriate excess volume and labeled vial fill sizes are two factors that may contribute to.. unsafe handling and injection practices by consumers and health care providers. FDA ..is publishing this guidance to clarify its regulatory 49 requirements and recommendations.
- A Bill Would Prevent Drug Makers From Frustrating Generic Rivals (blogs.wsj.com)
…second time …lawmakers...introduced a bill designed to end a practice that generic drug makers complain is used by brand-name counterparts to thwart competition…the Fair Access for Safe and Timely Generics Act,…follows accusations that brand-name drug makers exploit an FDA program known as Risk Evaluation and Mitigation Strategies,…
- Senators seek to save rural hospitals (washingtonexaminer.com)
Rural Emergency Acute Care Hospital Act. aims to cut red tape in an effort to keep rural hospitals' doors open… help rural hospitals,..which have started to close because of Medicare policies,..stay open by altering the rules…many…struggle to get enough patients to keep their status as a critical access hospital.
- California Caps What Patients Pay For Pricey Drugs. Will Other States Follow? (khn.org)
California agency that governs the state’s Affordable Care Act marketplace issued landmark rules recently that will limit the amount anyone enrolled in one of those plans can be charged each month for high-end medicine…agency said its rules,..“strike a balance …ensuring consumers can afford the medication they need to treat chronic and life-threatening conditions while keeping premiums affordable for all.”
- Tackling the very high costs of big health-care users (cnbc.com)
Imitation is the highest form of flattery.. new project is aiming to identify the kinds of treatments and models of care that lead to the best results for so-called high-need patients, and then try to replicate those results on a broad scale…

